SuperworthPrime Medicine price to book ratio PRME
Market value divided by the book value of the company's net assets, since 2023.
- Today, Oct 23, 2026
- 16.7×
- 4-year median
- 4.2×
- Against its 4-year history
- 98th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 1.1× to 18.2×
- Peer median
- 5.0×
Prime Medicine's price to book ratio is 16.7× as of Oct 23, 2026.
That is above its 4-year median of 4.2×, higher than on 98% of days in the last 4 years.
Over that time it ranged from 1.1× in Apr 2025 to 18.2× in Oct 2026.
The median for 4 biotech stocks of a similar size is 5.0×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 16.7× | 3.6× | 18.2× |
| 2025 | 3.9× | 1.1× | 14.0× |
| 2024 | 2.0× | 2.0× | 7.9× |
| 2023 | 4.4× | 2.3× | 5.6× |
Against its peers
Companies in Biotechnology nearest Prime Medicine's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| PRMEPrime Medicine | 16.7× |
| MGTXMeiraGTx | 4.1× |
| PLXProtalix BioTherapeutics | 2.9× |
| VCELVericel | 5.9× |
| ADMAAdma Biologics | 5.9× |
| Peer median | 5.0× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Prime Medicine
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.